DE578765T1 - Verabreichung von röntgenkontrastmitteln durch rezeptorvermittelte endocytose. - Google Patents
Verabreichung von röntgenkontrastmitteln durch rezeptorvermittelte endocytose.Info
- Publication number
- DE578765T1 DE578765T1 DE0578765T DE92910570T DE578765T1 DE 578765 T1 DE578765 T1 DE 578765T1 DE 0578765 T DE0578765 T DE 0578765T DE 92910570 T DE92910570 T DE 92910570T DE 578765 T1 DE578765 T1 DE 578765T1
- Authority
- DE
- Germany
- Prior art keywords
- saccharide
- group
- receptor
- composition
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000010837 receptor-mediated endocytosis Effects 0.000 title claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 11
- 238000000034 method Methods 0.000 claims 11
- 150000004676 glycans Chemical class 0.000 claims 7
- 229920001282 polysaccharide Polymers 0.000 claims 7
- 239000005017 polysaccharide Substances 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 230000008878 coupling Effects 0.000 claims 6
- 238000010168 coupling process Methods 0.000 claims 6
- 238000005859 coupling reaction Methods 0.000 claims 6
- 239000003550 marker Substances 0.000 claims 5
- 229920000189 Arabinogalactan Polymers 0.000 claims 4
- 229920002307 Dextran Polymers 0.000 claims 4
- 235000019312 arabinogalactan Nutrition 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 150000002256 galaktoses Chemical class 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 230000029087 digestion Effects 0.000 claims 3
- XWAVPOFYNPXXEL-MRVPVSSYSA-N (2r)-2-phenylmethoxypropanoic acid Chemical compound OC(=O)[C@@H](C)OCC1=CC=CC=C1 XWAVPOFYNPXXEL-MRVPVSSYSA-N 0.000 claims 2
- VAPDZNUFNKUROY-UHFFFAOYSA-N 2,4,6-triiodophenol Chemical compound OC1=C(I)C=C(I)C=C1I VAPDZNUFNKUROY-UHFFFAOYSA-N 0.000 claims 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical class OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- 239000001904 Arabinogalactan Substances 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 2
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims 2
- 229920000057 Mannan Polymers 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
- 150000001414 amino alcohols Chemical class 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 2
- 239000002872 contrast media Substances 0.000 claims 2
- 239000007857 degradation product Substances 0.000 claims 2
- 229930182830 galactose Chemical class 0.000 claims 2
- 229960003082 galactose Drugs 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 229960004537 ioversol Drugs 0.000 claims 2
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims 2
- 150000002704 mannoses Chemical class 0.000 claims 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- 229920000768 polyamine Polymers 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 238000005903 acid hydrolysis reaction Methods 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0442—Polymeric X-ray contrast-enhancing agent comprising a halogenated group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
- C08G18/1808—Catalysts containing secondary or tertiary amines or salts thereof having alkylene polyamine groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
- C08G18/1816—Catalysts containing secondary or tertiary amines or salts thereof having carbocyclic groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
- C08G18/1825—Catalysts containing secondary or tertiary amines or salts thereof having hydroxy or primary amino groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/18—Catalysts containing secondary or tertiary amines or salts thereof
- C08G18/20—Heterocyclic amines; Salts thereof
- C08G18/2009—Heterocyclic amines; Salts thereof containing one heterocyclic ring
- C08G18/2036—Heterocyclic amines; Salts thereof containing one heterocyclic ring having at least three nitrogen atoms in the ring
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/22—Catalysts containing metal compounds
- C08G18/24—Catalysts containing metal compounds of tin
- C08G18/244—Catalysts containing metal compounds of tin tin salts of carboxylic acids
- C08G18/246—Catalysts containing metal compounds of tin tin salts of carboxylic acids containing also tin-carbon bonds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/22—Catalysts containing metal compounds
- C08G18/26—Catalysts containing metal compounds of lead
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/04—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent
- C08J9/12—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
- C08J9/14—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent organic
- C08J9/143—Halogen containing compounds
- C08J9/144—Halogen containing compounds containing carbon, halogen and hydrogen only
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G2101/00—Manufacture of cellular products
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2375/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
- C08J2375/04—Polyurethanes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (21)
1. Verfahren zum Einbringen eines Röntgenkontrastmittel
in eine bestimmte Population von Zellen, umfassend
(i) das Herstellen eines Komplexes aus einem radiodichten Marker und einem Saccharid, das mit einem
Zellrezeptor wechselwirken kann; und (ii) das Erlauben, daß der Komplex durch rezeptorvermittelte Endozytose
von der bestimmten Population von Zellen aufgenommen wird.
2. Verfahren nach Anspruch 1, wobei das Saccharid ein Polysaccharid ist, ausgewählt aus Arabinogalactanen
und Mannanen sowie deren Abbauprodukte und Derivate, oder ein Monosaccharid ist, ausgewählt aus den Galactosen
und Mannosen.
3. Verfahren nach Anspruch 2, wobei das Saccharid ein Arabinogalactan ist oder eine Galactose, die mit organischen
Kopplungsgruppen modifiziert ist.
4. Verfahren nach Anspruch 3, wobei die organische Kopplungsgruppe
aus einer Aminopolycarbonsäure, einer Polycarbonsäure, einem Polyamin oder einem Aminoalkohol
besteht.
5. Verfahren nach Anspruch 4, wobei die organische Kopplungsgruppe
Diethylentriaminpentaessigsäure, Bernsteinsäure, Ethylendiamin oder Aminoethanol ist.
6. Verfahren nach einem vorangehenden Anspruch, wobei der radiodichte Marker eine iodhaltige Verbindung enthält.
7. Verfahren nach Anspruch 6, wobei der radiodichte Marker eine polyiodierte aromatische Gruppe oder eine
polyiodierte aliphatische Gruppe ist.
8. Verfahren nach Anspruch 7, wobei der radiodichte Marker eine Verbindung enthält, bestehend aus Ioversol,
Metrizonsäure, 2,4,6-Triiodphenol oder 2,3,5-Triiodbenzylalkohol.
9. Verfahren nach Anspruch 1, wobei das Saccharid ein modifiziertes Saccharid ist und erhältlich aus einem
Polysaccharid, das nicht zur rezeptorvermittelten Endozytose fähig ist, durch Anhängen von geeigneten
Substituentengruppen, die von RME-Rezeptoren erkannt werden, oder durch partiellen Verdau des Polysaccharids
.
10. Verfahren nach Anspruch 9, wobei das modifizierte Saccharid hergestellt wird aus einem Dextran und einer
Galactosegruppe oder einem Dextran und einer Mannosegruppe.
11. Verfahren nach Anspruch 9, wobei der Verdau durch Säurehydrolyse des Polysaccharids erfolgt.
12. Zusammensetzung zum Einbringen eines Röntgenkontrastmittels
in eine bestimmte Population von Zellen, enthaltend (i) ein Saccharid, das mit einem Zellrezeptor
wechselwirken und durch rezeptorvermittelte Endozytose aufgenommen werden kann, und (ii) einen radiodichten
Marker; wobei die Zusammensetzung von einer bestimmten Population von Zellen durch rezeptorvermittelte Endozytose
aufgenommen wird.
13. Zusammensetzung nach Anspruch 12, wobei das Saccharid ein Polysaccharid ist, ausgewählt aus Arabinogalactanen
und Mannanen sowie deren Abbauprodukte und Derivate, oder ein Monosaccharid ist, ausgewählt aus den
Galactosen und Mannosen.
14. Zusammensetzung nach Anspruch 13, wobei das Saccharic!
ein Arabinogalactan oder eine mit organischen Kopplungsgruppen modifizierte Galactose ist.
15. Zusammensetzung nach Anspruch 14, wobei die organische
Kopplungsgruppe aus einer Aminopolycarbonsäure, einer Polycarbonsäure, einem Polyamin oder einem Aminoalkohol
besteht.
16. Zusammensetzung nach Anspruch 15, wobei die organische KopplungsgruppeDiethylentriaminpentaessigsäure, Bernsteinsäure,
Ethylendiamin oder Aminoethanol ist.
. Zusammensetzung nach irgendeinem der Ansprüche 12 bis 16, wobei der radiodichte Marker eine iodhaltige Verbindung
enthält.
18. Zusammensetzung nach Anspruch 17, wobei der radiodichte Marker eine polyiodierte aromatische Gruppe
oder eine polyiodierte aliphatische Gruppe ist.
19. Zusammensetzung nach Anspruch 18, wobei der radiodichte Marker eine Verbindung enthält, bestehend aus Ioversol,
Metrizonsäure, 2,4,6-Triiodphenol und 2,3,5-Triiodbenzylalkohol.
20. Zusammensetzung nach Anspruch 12, wobei das Saccharid ein modifiziertes Saccharid ist und erhältlich aus
einem Polysaccharid, das keine rezeptorvermittelte Endozytose vornehmen kann, an das eine geeignete Substituentengruppe,
die von einem RME-Rezeptor erkannt wird, angehängt wird oder durch partiellen Verdau des
Polysaccharids.
21. Zusammensetzung nach Anspruch 20, wobei das modifizierte Saccharid aus einem Dextran und einer Galac-
tosegruppe oder einem Dextran und einer Mannosegruppe gebildet wird.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/679,526 US5141739A (en) | 1986-07-03 | 1991-04-02 | Delivery of x-ray contrast agents using receptor mediated endocytosis |
| PCT/US1992/002255 WO1992017216A1 (en) | 1991-04-02 | 1992-03-18 | Delivery of x-ray contrast agents using receptor mediated endocytosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE578765T1 true DE578765T1 (de) | 1994-05-26 |
Family
ID=24727269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE0578765T Pending DE578765T1 (de) | 1991-04-02 | 1992-03-18 | Verabreichung von röntgenkontrastmitteln durch rezeptorvermittelte endocytose. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5141739A (de) |
| EP (1) | EP0578765A1 (de) |
| JP (1) | JPH06506230A (de) |
| CA (1) | CA2105068A1 (de) |
| DE (1) | DE578765T1 (de) |
| ES (1) | ES2061423T1 (de) |
| GR (1) | GR940300022T1 (de) |
| WO (1) | WO1992017216A1 (de) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| GB8916782D0 (en) * | 1989-07-21 | 1989-09-06 | Nycomed As | Compositions |
| US5236694A (en) * | 1990-02-21 | 1993-08-17 | The Board Of Regents, The University Of Texas System | 19f labelled dextrans and antibodies as nmr imaging and spectroscopy agents |
| AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| DE4117782C2 (de) * | 1991-05-28 | 1997-07-17 | Diagnostikforschung Inst | Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel |
| JP2894879B2 (ja) * | 1991-10-04 | 1999-05-24 | 日本メジフィジックス株式会社 | 診断用造影剤 |
| US5342605A (en) * | 1992-05-01 | 1994-08-30 | Sterling Winthrop Inc. | Polymeric X-ray compositions containing iodinated polymeric beads |
| EP0665729B1 (de) * | 1992-09-04 | 2003-05-07 | The General Hospital Corporation | Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere |
| US5871710A (en) * | 1992-09-04 | 1999-02-16 | The General Hospital Corporation | Graft co-polymer adducts of platinum (II) compounds |
| US5340564A (en) * | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336923A (en) * | 1992-12-31 | 1994-08-09 | Honeywell, Inc. | Varactor diode having a stepped capacitance-voltage profile |
| US5342926A (en) * | 1993-06-08 | 1994-08-30 | The Regents Of The University Of California | Analogs of cytochalasin B as radiopharmaceuticals for nuclear imaging of trans-membrane glucose transport |
| US5605672A (en) * | 1993-06-09 | 1997-02-25 | The General Hospital Corporation | Blood pool imaging composition and method of its use |
| US6007845A (en) * | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US20030119724A1 (en) * | 1995-11-22 | 2003-06-26 | Ts`O Paul O.P. | Ligands to enhance cellular uptake of biomolecules |
| GB9705521D0 (en) | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
| DE19731591C2 (de) * | 1997-07-17 | 1999-09-16 | Schering Ag | Pharmazeutische Mittel enthaltend perfluoralkylgruppenhaltige Trijodaromaten und ihre Verwendung in der Tumortherapie und interventionellen Radiologie |
| US6245316B1 (en) | 1997-10-08 | 2001-06-12 | David Platt | Enhancement of delivery of radioimaging and radioprotective agents |
| US6093382A (en) | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
| US6723746B2 (en) | 1998-09-08 | 2004-04-20 | Veritas Pharmaceuticals, Inc. | Functional radiographic imaging methods and agents |
| US6226352B1 (en) * | 1998-09-08 | 2001-05-01 | Veritas Pharmaceuticals, Inc. | System and method for radiographic imaging of tissue |
| US6751290B2 (en) | 1998-09-08 | 2004-06-15 | Veritas Pharmaceuticals, Inc. | Radiographic assessment of tissue after exposure to a compound |
| US6426145B1 (en) | 1999-05-20 | 2002-07-30 | Scimed Life Systems, Inc. | Radiopaque compositions for visualization of medical devices |
| FR2802817B1 (fr) * | 1999-12-23 | 2002-10-11 | Centre Nat Rech Scient | Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete |
| US7169618B2 (en) * | 2000-06-28 | 2007-01-30 | Skold Technology | Magnetic particles and methods of producing coated magnetic particles |
| CA2431839A1 (en) | 2000-12-01 | 2002-06-06 | Paul O. P. Ts'o | Conjugates of glycosylated/galactosylated peptide |
| EP1390078A4 (de) * | 2001-04-26 | 2005-10-26 | Analogic Corp | Ct-scanner für die darstellung eines vorab festgelegten teils eines patienten |
| WO2002100444A1 (en) * | 2001-06-08 | 2002-12-19 | Biosphere Medical Inc. | Colloidal metal labelled microparticles, their production and use |
| US7019035B2 (en) * | 2004-05-17 | 2006-03-28 | Md Scientific Llc | Method for attenuating free radical formation resulting from bodily insult |
| US20050255175A1 (en) * | 2004-05-17 | 2005-11-17 | Burgess W P | Method for protecting nephron against injury caused by disruption of a chemical environment in the kidneys |
| US20050255176A1 (en) * | 2004-05-17 | 2005-11-17 | Burgess W P | Method for attenuating free radical formation resulting from bodily insult |
| US7625586B2 (en) | 2004-10-28 | 2009-12-01 | Md Scientific, Llc | Method for mitigating injury to a kidney resulting from an ischemic event |
| KR100695744B1 (ko) | 2005-05-03 | 2007-03-19 | 한국원자력연구소 | 디티피에이(ｄｔｐａ) 유도체 및 이들을 이용한 금속 착화물, 이들을 포함하는 방사선원 및 조영제 |
| CN1966088B (zh) * | 2006-11-16 | 2010-09-29 | 中国科学院长春应用化学研究所 | 阿拉伯半乳聚糖为载体的磁共振成像造影剂 |
| CA2719623A1 (en) * | 2008-03-24 | 2009-10-01 | The Board Of Regents Of The University Of Texas System | Image-guided therapy of myocardial disease: composition, manufacturing and applications |
| JP2013502263A (ja) | 2009-08-18 | 2013-01-24 | ベン‐グリオン ユニバーシティ オブ ザ ネゲヴ リサーチ アンド デベロップメント オーソリティ | 撮像データを解析するためのシステムおよび方法 |
| US9827265B1 (en) | 2012-04-06 | 2017-11-28 | Md Scientific, Llc | Method for attenuating free radical formation resulting from a bodily insult |
| WO2014152488A2 (en) * | 2013-03-15 | 2014-09-25 | Dreher Matthew R | Imageable embolic microsphere |
| EP3506916B1 (de) | 2016-09-01 | 2021-04-07 | Chimera Bioengineering Inc. | Goldoptimierte auto-t-zellen |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR6024559D0 (pt) * | 1959-12-08 | 1973-05-31 | Nyegaard & Co As | Processo para preparacao de novos derivados de acido 3 5-diamino-2 4 6-triiodo benzoico ou semi sais nao toxicos bem como de agentes ou meios de contraste para raios x baseados nos mesmos |
| IT1053508B (it) * | 1970-07-06 | 1981-10-10 | Searle & Co | Procedimento per prepare composizioni marcate adatte a mettere in evidenza alterazioni della mucosa gastrointestinale prodotto ottenuto e relativo metodo di impiego |
| US4069306A (en) * | 1974-03-14 | 1978-01-17 | Pharmacia Aktiebolag | X-ray contrast preparation containing a hydrophilic polymer containing amino groups |
| US4038379A (en) * | 1976-03-24 | 1977-07-26 | Nikolai Petrovich Elinov | Composition for roentgenoscopy of the gastrointestinal tract containing a polysaccharide stabilizer |
| US4243653A (en) * | 1979-04-27 | 1981-01-06 | The Regents Of The University Of California | Non-ionic polyiodo sugar substituted anilines |
| US4431626A (en) * | 1981-05-27 | 1984-02-14 | The Regents Of The University Of California | Tc-99m Labeled carrier for imaging |
| US4501726A (en) * | 1981-11-12 | 1985-02-26 | Schroeder Ulf | Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof |
| US4396598A (en) * | 1982-01-11 | 1983-08-02 | Mallinckrodt, Inc. | Triiodoisophthalamide X-ray contrast agent |
| FR2550449B1 (fr) * | 1983-08-12 | 1986-01-31 | Commissariat Energie Atomique | Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire |
| CA1224003A (en) * | 1984-04-24 | 1987-07-14 | Robert S. Molday | Colloidal sized metal-polysaccharide particles |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| SE465907B (sv) * | 1984-11-01 | 1991-11-18 | Nyegaard & Co As | Diagnosticeringsmedel innehaallande en paramagnetisk metall |
| US4675173A (en) * | 1985-05-08 | 1987-06-23 | Molecular Biosystems, Inc. | Method of magnetic resonance imaging of the liver and spleen |
| US4770183A (en) * | 1986-07-03 | 1988-09-13 | Advanced Magnetics Incorporated | Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents |
| US4827945A (en) * | 1986-07-03 | 1989-05-09 | Advanced Magnetics, Incorporated | Biologically degradable superparamagnetic materials for use in clinical applications |
| US4822594A (en) * | 1987-01-27 | 1989-04-18 | Gibby Wendell A | Contrast enhancing agents for magnetic resonance images |
| US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
| EP0381742B1 (de) * | 1988-08-04 | 1996-06-19 | Advanced Magnetics Incorporated | Von einem rezeptor induziertes kontrastmittel für den endocytose-typ mri |
| EP0433312A4 (en) * | 1988-08-24 | 1991-12-04 | The University Of Connecticut | Carrier system and method for enhancement of magnetic resonance imaging |
| EP0361960A3 (de) * | 1988-09-29 | 1992-01-02 | RANNEY, David F. | Verfahren und Vorrichtung zur Bilderzeugung mittels magnetischer Resonanz |
| US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
| GB8919929D0 (en) * | 1989-09-04 | 1989-10-18 | Nycomed As | Compositions |
-
1991
- 1991-04-02 US US07/679,526 patent/US5141739A/en not_active Expired - Fee Related
-
1992
- 1992-03-18 CA CA002105068A patent/CA2105068A1/en not_active Abandoned
- 1992-03-18 JP JP4509688A patent/JPH06506230A/ja active Pending
- 1992-03-18 EP EP92910570A patent/EP0578765A1/de not_active Ceased
- 1992-03-18 ES ES92910570T patent/ES2061423T1/es active Pending
- 1992-03-18 DE DE0578765T patent/DE578765T1/de active Pending
- 1992-03-18 WO PCT/US1992/002255 patent/WO1992017216A1/en not_active Application Discontinuation
-
1994
- 1994-04-29 GR GR940300022T patent/GR940300022T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2061423T1 (es) | 1994-12-16 |
| GR940300022T1 (en) | 1994-04-29 |
| CA2105068A1 (en) | 1992-10-03 |
| EP0578765A1 (de) | 1994-01-19 |
| JPH06506230A (ja) | 1994-07-14 |
| WO1992017216A1 (en) | 1992-10-15 |
| US5141739A (en) | 1992-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE578765T1 (de) | Verabreichung von röntgenkontrastmitteln durch rezeptorvermittelte endocytose. | |
| DE69432705T2 (de) | Zusammensetzung zur sichtbarmachung von blutstauungen und ihre anwendungsmethoden | |
| DE69823055T2 (de) | Verabreichung von polyethylenglykol-konjugierten Molekülen aus abbaubaren Hydrogelen | |
| DE69429169T2 (de) | Pharmazeutisches präparat, das heparin, heparinfragmente oder -derivate in kombination mit glycerinestern enthält | |
| DE69327490T2 (de) | Arzneimittel aus Polymer-Micellen mit physikalischer Einschlusswirkung | |
| DE69417035T2 (de) | Heparinderivate mit antimetastatischer wirkung | |
| DE69025270T2 (de) | Verwendung von Monoolein bei der Behandlung der Periodontal- tasche | |
| EP0794767A1 (de) | Stabile budesonid-lösungen, verfahren zu deren herstellung sowie verwendung dieser lösungen als klistierzubereitungen und pharmazeutische schäume | |
| DE1767891B2 (de) | Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat | |
| DE2240782A1 (de) | Verfahren zur herstellung eines eisensaccharid-komplexes | |
| DE3020649A1 (de) | Transparenter reinigungsmittel- formling | |
| DE60115478T2 (de) | Bei niedriger Temperatur wärmeaktivierte Klebstoffe mit hoher Wärmebeständigkeit | |
| DE10207072A1 (de) | Stärkederivate, ihre Konjugate und Verfahren zur Herstellung derselben | |
| DE563249T1 (de) | Targeting von therapeutischen mitteln durch verwendung von polysacchariden. | |
| DE69630727T2 (de) | Radioaktiven Chitosankomplex und deren Anwendung in Strahlungstherapie | |
| DE68904617T2 (de) | Jodhaltige polymere mit skeletten von dextran, verfahren zu ihrer herstellung und ihre verwendungen als kontrastmittel. | |
| DE2346774A1 (de) | Roentgenkontrastmittel | |
| DE69214215T2 (de) | Magnetisches Kernresonanz Bilderzeugungsmittel | |
| DE1595012A1 (de) | OElloesliche Diisocyanataddukte | |
| DE60001489T2 (de) | Pharmazeutische zubereitung für die intravenöse oder intramuskuläre verabreichung von octreotid | |
| AT392904B (de) | Verfahren zur herstellung einer zur oralen verabreichung von etoposid bestimmten weichgelantinekapsel | |
| DE3942143A1 (de) | T-pa pro stabilisierung | |
| DE4217916C2 (de) | N-Alkylamin- und N-Arylalkylaminderivate von Heparin, Verfahren zu ihrer Herstellung und ihrer Verwendung | |
| DE2602363C2 (de) | Wäßrige, injizierbare Niclofolan- Formulierungen | |
| EP0593633B1 (de) | Metabolisierbarer plasmaersatz |